ABSTRACT
Reports have highlighted a shortage of consultant diabetologist posts in the UK. The number of doctors completing specialist training in diabetes has increased in recent years, but little is known about their employment after they receive their certificate of completion of training. An online survey was sent to all doctors who completed specialist diabetes training from January 2008 to September 2010. Of the 95 eligible respondents, 69 (73%) completed the survey (61% men; median age 36 years). Forty-three (62%) respondents secured substantive NHS consultant posts, and of those who gave their job breakdown, 48/51 (94%) were contributing to specialist diabetes care. Five (7%) respondents held substantive academic positions, while 11 (16%) were locum consultants. Seven (9%) respondents worked abroad, with half of these attributing their emigration to lack of opportunities in the UK. When asked about alternative choices, 39% of respondents were likely to seek 'general physician' roles, which equalled the number who would consider emigrating. Overall, only two-thirds of doctors who complete specialist training in diabetes secure substantive NHS consultant positions, which suggests a failure in workforce planning and a lack of expansion of the number of consultant posts despite progression of the diabetes epidemic.
Subject(s)
Consultants/statistics & numerical data , Education, Medical, Continuing/organization & administration , Endocrinology/education , Job Application , Personnel Staffing and Scheduling/organization & administration , Diabetes Mellitus , Education/organization & administration , Employment , Health Care Surveys , Health Services Needs and Demand , Humans , Medical Staff/statistics & numerical data , State Medicine/organization & administration , Surveys and Questionnaires , United KingdomABSTRACT
BACKGROUND: Cushing's syndrome (CS) is a severe condition with excess mortality and significant morbidity necessitating control of hypercortisolemia. There are few data documenting use of the steroidogenesis inhibitor metyrapone for this purpose. OBJECTIVE: The objective was to assess the effectiveness of metyrapone in controlling cortisol excess in a contemporary series of patients with CS. DESIGN: This was designed as a retrospective, multicenter study. SETTING: Thirteen University hospitals were studied. PATIENTS: We studied a total of 195 patients with proven CS: 115 Cushing's disease, 37 ectopic ACTH syndrome, 43 ACTH-independent disease (adrenocortical carcinoma 10, adrenal adenoma 30, and ACTH-independent adrenal hyperplasia 3). MEASUREMENTS: Measurements included biochemical parameters of activity of CS: mean serum cortisol "day-curve" (CDC) (target 150-300 nmol/L); 9 am serum cortisol; 24-hour urinary free cortisol (UFC). RESULTS: A total of 164/195 received metyrapone monotherapy. Mean age was 49.6 ± 15.7 years; mean duration of therapy 8 months (median 3 mo, range 3 d to 11.6 y). There were significant improvements on metyrapone, first evaluation to last review: CDC (91 patients, 722.9 nmol/L [26.2 µg/dL] vs 348.6 nmol/L [12.6 µg/dL]; P < .0001); 9 am cortisol (123 patients, 882.9 nmol/L [32.0 µg/dL] vs 491.1 nmol/L [17.8 µg/dL]; P < .0001); and UFC (37 patients, 1483 nmol/24 h [537 µg/24 h] vs 452.6 nmol/24 h [164 µg/24 h]; P = .003). Overall, control at last review: 55%, 43%, 46%, and 76% of patients who had CDCs, UFCs, 9 am cortisol less than 331 nmol/L (12.0 µg/dL), and 9 am cortisol less than upper limit of normal/600 nmol/L (21.7 µg/dL). Median final dose: Cushing's disease 1375 mg; ectopic ACTH syndrome 1500 mg; benign adrenal disease 750 mg; and adrenocortical carcinoma 1250 mg. Adverse events occurred in 25% of patients, mostly mild gastrointestinal upset and dizziness, usually within 2 weeks of initiation or dose increase, all reversible. CONCLUSIONS: Metyrapone is effective therapy for short- and long-term control of hypercortisolemia in CS.
Subject(s)
Cushing Syndrome/drug therapy , Enzyme Inhibitors/therapeutic use , Metyrapone/therapeutic use , ACTH-Secreting Pituitary Adenoma/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Dose-Response Relationship, Drug , Drug Therapy, Combination , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/adverse effects , Humans , Hydrocortisone/blood , Hydrocortisone/urine , Infant , Male , Metyrapone/administration & dosage , Metyrapone/adverse effects , Middle Aged , Pituitary Neoplasms/drug therapy , Retrospective Studies , Treatment Outcome , Young AdultABSTRACT
The improved survival of patients irradiated for central nervous system (CNS) and head and neck malignancy plus the recognition of the frequency of hypopituitarism following traumatic brain injury and other insults to the CNS has greatly increased the number of patients requiring long-term monitoring of pituitary function. The investigation of pituitary reserve requires knowledge of the risk factors for the development of hypopituitarism and thus biochemical testing is underpinned by the need for a meticulously taken medical history and careful examination of the patient. Radiology may be of value in establishing the etiology of hypopituitarism but the diagnosis is based on biochemical evaluation. This chapter provides a rational approach to the investigation of patients at risk of hypopituitarism including descriptions of how to undertake and interpret basal and dynamic tests of pituitary function.